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Kinetics, dynamics, and bioavailability of 
bumetanide in healthy subjects and 
patients with chronic renal failure 
Six patients with chronic renal failure (CRF group) and four healthy subjects (HS group) were given 5 
mg oral and intravenous doses of bumetanide in a random, crossover design. The CRF group had 
significantly lower plasma and renal clearances, resulting in a five- to sixfold reduction in the fractional 
urinary excretion of the drug. The percent free drug in plasma for the CRF group was more than double 
that for the HS group, and significant correlations were observed for volume of distribution at steady 
state vs. percent free (r = 0.661; P < 0.05), nonrenal clearance vs. percent free (r = 0.796; P < 0.01), 
and renal clearance vs. creatinine clearance (r = 0.995; P < 0.001). Although bioavailability was relatively 
consistent among the HS (0.664 ± 0.112) and CRF (0.689 ± 0.149) groups, the absorption-time profiles 
were more irregular for both groups. Cumulative sodium excretion and overall efficiency of response to 
bumetanide did not differ significantly between the two routes of administration in either group. (CLIN 
PHARmAcoL TITER 1986;39:635-45.) 
Henry S. H. Lau, Ph.D.,* Martha L. Hyneck, Pharm.D., 
Rosemary R. Berardi, Pharm.D., Richard D. Swartz, M.D., and 
David E. Smith, Ph.D. Ann Arbor, Mich. 
Bumetanide (3-n-butylamino-4-phenoxy-5-sulfa- 
moyl-benzoic acid) is a potent loop diuretic that is sim- 
ilar to furosemide with respect to its pharmacologic 
action and clinical indications.' Its principal site of 
action is the thick ascending limb of the loop of 
Henle,2-4 where it has been shown to exert its natriuretic 
and diuretic effects from the luminal surface of 
the nephron.4 Because bumetanide is highly protein 
bound,5-7 glomerular filtration is a minor mechanism for 
drug excretion. Instead, bumetanide gains access to the 
kidney lumen through the nonspecific organic acid se- 
cretory pathway.8-1° As a result, any pathophysiologic 
condition that affects the renal tubular secretion of 
bumetanide can thereby modify its dose-response re- 
lationship. 
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Furosemide is typically used as therapy for patients 
with edematous states associated with a variety of dis- 
eases, including renal dysfunction." However, the 
drug's pharmacodynamics are quite variable and sub- 
optimal responses can occur, particularly after oral dos- 
ing.'" The inability to predict a satisfactory clinical 
response for furosemide may be due, in part, to the 
extensive variability in its bioavailability."4-16 In con- 
trast, bumetanide has been reported to have a consis- 
tently high extent of systemic availability in healthy 
subjects''''' and in patients with hepatic or renal dis- 
ease." Nonetheless, pharmacokinetic and pharmaco- 
dynamic data for bumetanide in patients with chronic 
renal failure (CRF) are very limited,7'20 and no such 
studies have been performed at therapeutic doses in 
these patients. Therefore, we proposed (1) to study the 
absorption and disposition of bumetanide in patients 
with CRF after 5 mg oral and intravenous doses, and 
(2) to determine if parenteral administration of bumet- 
anide offers any advantage over oral dosing in eliciting 
sufficient natriuresis and diuresis. Parallel studies were 
performed in healthy subjects (HS group) for the pur- 
pose of comparison. 
METHODS 
Materials. Bumetanide tablets (1 mg; lot 0303-1) and 
intravenous solution (0.25 mg/ml; lot 0103) were ob- 
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Table I. Clinical data of healthy subjects and patients with CRF 
*Determined over 24 hours. 
tamed from Hoffmann-La Roche, Inc. All other chem- 
icals and solvents were reagent grade or better, as pre- 
viously reported 21 
Study participants. This study was performed in the 
Clinical Research Center of the University of Michigan 
Hospitals. The control group consisted of four healthy 
subjects, as judged by medical history, physical ex- 
amination, and standard laboratory tests, including a 
creatinine clearance determination (Table I). The pa- 
tient group consisted of six individuals with moderate 
to severe CRF and a stable creatinine clearance (CI,cR) 
of <30 ml/min (Table I). Patients were excluded from 
the study if they had diabetes or signs or symptoms of 
hepatic, hematologic, or gastrointestinal diseases. All 
diuretics were withheld for 24 hours before each study 
day and drugs that have diuretic-like properties (i.e., 
theophylline) or that may inhibit the diuretic response 
(i.e., nonsteroidal anti-inflammatory drugs) were not 
allowed for a minimum of 3 days before bumetanide 
administration. Patients were instructed to adhere 
strictly to their prescribed dietary restrictions and each 
participant was asked to avoid caffeine-containing bev- 
erages throughout the study. All participants were fully 
informed of the nature of the study and signed an in- 
formed consent form approved by the Committee to 
CLIN PHARMACOL THER 
JUNE 1986 
Review Grants for Clinical Research and Investigation 
Involving Human Beings of the University of Michigan 
Medical Center. 
Study design. After an overnight fast, each partici- 
pant received a 5 mg dose of bumetanide, either orally 
(five tablets) or intravenously, at 8 AM in a randomized 
crossover design. A period of at least 1 week elapsed 
between the two dosing regimens. Bumetanide tablets 
were taken with 8 oz water; the solution was infused 
at a constant rate over 3 minutes. For the intravenous 
dose, serial blood samples (3 ml) were drawn from the 
contralateral arm through an indwelling heparinized (10 
U/ml) scalp vein needle and drawn into tubes containing 
EDTA at 0, 3, 5, 10, 20, 30, 45, 60, 90, 120, 150, 
180, 240, 300, 360, 480, and 1440 minutes after the 
start of the infusion. For the oral dose, serial blood 
samples were drawn at 0, 15, 30, 45, 60, 90, 120, 150, 
180, 240, 300, 360, 420, 480, and 1440 minutes after 
drug dosing. Blood samples were centrifuged imme- 
diately and the plasma was harvested and frozen. 
Voided urine was collected from 24 to 0 (blank), 0 
to 0.5, 0.5 to 1.0, 1.0 to 1.5, 1.5 to 2.0, 2.0 to 2.5, 
2.5 to 3.0, 3 to 4, 4 to 5, 5 to 6, 6 to 7, 7 to 8, 
and 8 to 24 hours relative to drug dosing. Plasma and 
urine samples were stored at 20° C until subsequent 
Sex 
Age 
(yr) 
Weight 
(kg) 
Serum 
albu- 
min 
(gm/dl) 
BUN 
(mg/dl) 
CL,* 
(ml/mm) Diagnosis Concomitant drugs 
Subjects 
1 F 23 51.7 5.4 6 92.6 Healthy 
2 M 32 67.8 4.8 17 107 Healthy 
3 F 22 68.5 4.8 7 95.5 Healthy 
4 M 27 62.4 4.9 19 130 Healthy 
R 26 62.6 5.0 12 106 
± SD 5 7.8 0.3 7 17 
Patients 
5 F 48 69.2 4.8 81 17.4 Chronic intersti- 
tial nephritis 
Methyldopa, allopurinol, hydral- 
azine, metoprolol tartrate 
6 M 59 73.0 4.3 43 20.5 Hypertension Propranolol HC1, isosorbide dini- 
trate, dipyridamole 
7 F 51 106 4.4 51 12.4 Myeloma Allopurinol 
8 M 68 69.0 4.2 74 7.3 Hypertension Multivitamin 
9 F 47 104 4.0 43 28.6 Polycystic kidney 
disease 
Metoprolol tartrate, multivitamin 
10 M 41 87.6 4.1 61 24.0 Wegener's 
disease 
Hydralazine, folic acid, cyclophos- 
phamide, atenolol 
52 84.8 4.3 59 18.4 
± SD 10 17.1 0.3 16 7.7 
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analysis. Participants were kept relatively euvolemic 
throughout the study by drinking fruit juices in a volume 
equal to the urine passed during the previous time pe- 
riod. Lunch was provided 4 hours after dosing and all 
plasma samples showed normal sodium concentrations. 
Analytic procedures. Plasma and urine samples con- 
taining bumetanide were assayed by a rapid, sensitive, 
and specific HPLC method, as described previously by 
Smith.' Sodium concentrations were measured with a 
flame photometer. 
Protein binding. The plasma protein binding of 
bumetanide was determined for each participant with 
the use of from three to seven data points from the 
intravenous drug profile. Plasma, 0.5 ml, was dialyzed 
against an equal volume of isotonic phosphate buffer 
(0.067 mol/L at pH 7.4) at 37° C for 6 hours. Dialysis 
membranes (molecular weight cutoff 12,000 to 14,000 
daltons) and 1 ml equilibrium dialysis cells were used 
throughout, and preliminary studies indicated that 
equilibrium was achieved within 2 hours and remained 
constant for 24 hours. Dialyzed buffer (0.2 ml) was 
then mixed with 50 pJ acetophenone (0.25 mg/ml) and 
injected into the HPLC system, as reported previously.' 
A typical standard curve of bumetanide/acetophenone 
peak height ratio over the bumetanide buffer concen- 
tration range of 5.2 to 206 ng/ml resulted in the 
following linear least-squares regression equation: 
Y 0.0213X + 0.0096 (r2 = 0.9997). The percent 
of unbound bumetanide in the original plasma sample 
(fu) was calculated as: fu = 100/(C/C,' 1), where C 
represents the measured total concentration of drug in 
plasma before dialysis and C,' represents the measured 
unbound concentration of drug in buffer after dialysis. 
This equation was originally developed by Tozer et al.22 
to correct for the volume shift that can occur during 
equilibrium dialysis. It assumes that the initial plasma 
and buffer volumes are equal, that protein binding is 
linear, and that there is negligible binding of drug to 
the dialysis membrane (mean value of 1.24% for bu- 
metanide). 
Kinetics. Plasma concentration-times curves of bu- 
metanide were fit (weighting factor of 1/C2) to the gen- 
eral polyexponential equation for postconstant-rate in- 
fusion data' 
C = EYe (1) 
i = 1 
where C is the plasma concentration at time t, n is the 
number of exponents, Y, is the coefficient of the ith 
exponential term for postconstant-rate intravenous in- 
fusion data, and A. is the exponent of the ith exponential 
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term. Initial estimates of the coefficients and exponen- 
tial terms in Eq. 1 were obtained by use of the program 
RSTRIP (personal communication); their final esti- 
mates were obtained by use of the nonlinear least- 
squares regression program NONLIN.' The number of 
exponents needed for each data set was determined by 
the application of Akaike's information criterion.' 
Because 
C = E(1 - eiT)Cie-xit/( AT) (2) 
where T is the constant-rate infusion time and C, is the 
coefficient of the ith exponential term for bolus intra- 
venous data, Eq. 1 can be rearranged to the correspond- 
ing equation': 
Y, = E(1 - exT)C,/( X,T) (3) 
I 
Once the values of the coefficients and exponential 
terms in Eq. 1 are determined by computer fitting, the 
values of C, in Eq. 3 can be calculated. 
The following pharmacokinetic parameters were cal- 
culated from standard equations"'": 
V. = D/ E C, (4) 
in which V. is the volume of the central compartment; 
D is the intravenous dose (equal to the product of the 
zero-order infusion rate and the length of infusion); CI 
and X, are the coefficient and exponent, respectively, 
such that X, is the smallest of the X, values of the 
polyexponential equation; V. is the volume of distri- 
bution at steady state; Va,ea is the volume that, when 
multiplied by C in the log-linear phase, is equal to the 
amount of drug in the body; CL is the total plasma 
clearance; CL,, is the renal clearance; Ae(0-00) is the 
= D E Ci/X,2/(E Ci/X,)2 (5) 
-1 
V,,,, = D/(X, E Ci/X,) (6) 
CL = D/ E Ci/X, (7) 
CL,, = Ae(0-00)/ E C/A, 
, 
(8) 
CLNR = CL CLR (9) 
ty2 = 0.693/X1 (10) 
klo = CL/V, 
f, = Ae(0-0)/D 
(11) 
(12) 
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Fig. 1. Mean ( -± SE) plasma concentration-time profiles of 
bumetanide in healthy subjects after 5 mg oral () and intra- 
venous (*) doses. 
amount of unchanged drug recovered in the urine at 
time infinity; CLNR is the nonrenal clearance; 1c10 is the 
first-order elimination rate constant from the central 
compartment; and fe is the fraction of the available dose 
excreted unchanged in the urine. 
Plasma concentration-time profiles of oral bumet- 
anide were not computer-fit because of irregular ab- 
sorption profiles in many of the participants. Pertinent 
kinetic parameters were, therefore, calculated by a non- 
compartmental approach. The biologic t112 was graph- 
ically determined by linear regression with use of at 
least four data points from the log-linear terminal phase, 
and CLR was determined by division of Ae(0-ao) by the 
plasma AUC(0-00), calculated by a combination of the 
trapezoidal and log-trapezoidal rules and extrapolated 
to infinity by Cia./X . The peak plasma concentration 
(C,,,R) and time to peak (tmax) after an oral dose were 
read directly from the plasma concentration-time curve. 
Bioavailability. The extent of systemic availability 
of bumetanide was calculated by area ratios of oral 
(subscript po) and intravenous (subscript iv) dosing 
(Fp = AUC(0-00),/AUC(0-00)), by urinary excretion 
ratios (Fu = Ae(0-00),/Ae(0-a0),), and by correction 
for differences in CLR between oral and intravenous 
i0000; 
1000 
100 
10 
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Fig. 2. Mean (± SE) plasma concentration-time profiles of 
bumetanide in patients with CRF after 5 mg oral () and 
intravenous (*) doses. 
doses (extrapolated to infinity) as suggested by Oie and 
Jung': 
(D,, Aelv)AUC/AUC,, + Ae, (13) 
For the calculations of Fp and Fvorr, AUC,v was deter- 
mined by a combination of the trapezoidal and log- 
trapezoidal rules, extrapolated to infinity by CiastAl 
The computer-fitted and noncompartmental estimates 
of AUC,, differed from one another by <2%. 
The mean absorption time (MAT) was used as a mea- 
sure of the absorption rate of oral bumetanide by use 
of the noncompartmental method of statistical mo- 
ments.''' MAT was calculated as the difference of 
mean residence times (MRT) between oral and in- 
travenous dosing: MAT = MRT, MRT,v, where 
MRT equals the area under the first moment curve 
(AUMC; extrapolated to infinity) divided by AUC(0-ac). 
The AUMC was estimated by a combination of the 
trapezoidal and log-trapezoidal rules, extrapolated to 
infinity by tiast Clast/X, + Ciast/X,2. An MAT value that 
corrects for the time lag (tag) before drug absorption 
was also reported (MAT, = MAT tug). The tlag 
was estimated from absorption profiles using the exact 
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Table II. Coefficients and exponential terms of intravenous bumetanide in healthy subjects and patients 
with CRF determined by bi- and triexponential equations 
NS Not significant. 
Loo-Riegelman equation of Wagner' and the second 
derivative criterion of Proost31 for evaluation of the two 
integrals of that equation. 
Dynamics. Pharmacodynamic data were reported as 
the 8-hour cumulative excretion of sodium and the over- 
all efficiency (Eff ) of the response: Eff = (AE - 
AE0)/AAe, where AE and AAe are the amount of so- 
dium and drug excreted in urine, respectively, and AEo 
is the baseline effect over the same 8-hour period. 
The relationship between the sodium excretion rate 
(E; in milliequivalents per minute) and urinary excretion 
rate of bumetanide (ER; in micrograms per minutes) 
was evaluated by the sigmoid Erna, E = 
Em ax ERs/(ER50s + ERs) + E0, where Ema is the 
maximum effect attributable to the drug, ER50 is the 
urinary excretion rate of drug producing 50% of Erna., 
Eo is the baseline effect, and S is the parameter influ- 
encing the slope of the dose-effect curve. The unknown 
parameters (Em, ER50, E0, and S) were determined 
*R2 = [I(Obs)2 - /(Dev)21//(Obs)2, where /(Dev)2 is the residual sum of squares. 
tCORR represents the correlation between the calculated and observed plasma concentrations. 
Table III. Pharmacokinetic parameters after intravenous bumetanide in healthy subjects and patients with CRF 
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after intravenous dosing of bumetanide for each indi- 
vidual by use of the NONLIN32 program and a weight- 
ing factor of unity. 
Statistics. Unless otherwise indicated, data are ex- 
pressed as the X -± SD. Statistical differences between 
the HS and CRF groups were determined by a two- 
sample t test. Statistical differences between oral and 
intravenous dosing within each group were determined 
by a paired t test. The linear relationship between two 
variables was assessed by the correlation coefficient r. 
A P value was considered significant. 
RESULTS 
Semilogarithmic plots of the plasma concentration- 
time curves of intravenous and oral bumetanide are 
shown in Figs. 1 and 2 for healthy subjects and patients 
with CRF, respectively. After intravenous infusion, 
plasma concentrations of bumetanide were fit to a biex- 
ponential equation for four data sets and to a triexpo- 
C(1) 
(nglml) 
C(2) 
(nglml) 
C(3) 
(nglml) 
A, 
(min- ') 
A2 (min') 
A, 
(min") 1?2* CORRt 
Subjects 
1 24.7 623 1094 0.0041 0.0185 0.1333 0.991 0.992 
2 281 1080 0.0141 0.1329 0.996 0.997 
3 83.0 725 1094 0.0078 0.0321 0.1769 1.000 1.000 
4 129 812 0.0113 0.0394 0.994 0.994 
Patients 
5 324 1265 0.0096 0.1412 0.999 1.000 
6 189 384 1512 0.0053 0.0184 0.1799 0.998 0.998 
7 161 446 1338 0.0077 0.0581 0.3040 1.000 1.000 
8 403 735 0.0077 0.1202 0.998 0.998 
9 58.9 322 984 0.0033 0.0162 0.1612 0.990 0.992 
10 58.3 282 625 0.0053 0.0171 0.2056 1.000 1.000 
Subjects Patients Significance (P value) 
CL (ml/min kg) 2.25 ± 0.37 1.40 ± 0.32 <0.01 
CLR (ml/min kg) 1.46 ± 0.20 0.153 ± 0.079 <0.001 
CLNR (ml/min kg) 0.790 -± 0.304 1.25 ± 0.33 NS 
tit, (mm) 92.2 ± 53.9 121 ± 50 NS 
(min-') 0.0407 ± 0.0094 0.0351 ± 0.0130 NS 
V. (L/kg) 0.0584 ± 0.0194 0.0434 ± 0.0156 NS 
(L/kg) 0.122 ± 0.019 0.147 ±- 0.024 NS 
V_ (L/kg) 0.285 ± 0.140 0.234 ± 0.084 NS 
Ae (%) 65.4 ± 8.1 11.4 ± 6.8 <0.001 
(%) 0.588 ± 0.058 1.36 0.37 <0.005 
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Fig. 3. A, Relationship between and bumetanide fu in 
healthy subjects (*) and patients with CRF (; r = 0.661; 
P < 0.05). B, Relationship between CLNR and bumetanide f 
in healthy subjects (*) and patients with CRF (; r = 
0.796; P < 0.01). 
nential equation for six data sets (Table II). The good- 
ness of fit was evaluated by R2 (.- --0.990) CORR 
(-0.992) and by visual examination of the residuals. 
Kinetic data after intravenous bumetanide are listed 
in Table III. In comparison with the HS group, the CRF 
group had a significantly lower CI, (1.46 ± 0.20 ml/ 
min kg for the HS group vs. 0.153 ± 0.079 ml/ 
min kg for the CRF group; P <0.001) and CL 
(2.25 0.37 ml/min kg for the HS group vs. 
1.40 ±.- 0.32 ml/min kg for the CRF group; P < 
0.01), resulting in a five- to sixfold reduction in the fe 
value of the diuretic (0.654 0.081 for the HS group 
vs. 0.114 ± 0.068 for the CRF group; P < 0.001). 
Although the volume terms and CL, did not differ 
statistically between the two groups, a significant cor- 
relation was observed between V and fu (Fig. 3, A; 
r = 0.661; P <0.05) and CI, and fu (Fig. 3, B; 
r = 0.796; P < 0.01), reflecting the greater than dou- 
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ble increase in bumetanide fi, in the CRF group. The 
biologic t112 and kio values did not differ between the 
HS and CRF groups. 
Kinetic data after oral bumetanide are listed in Table 
IV. No significant differences were observed between 
the two groups, except for CL,, (1.71 ± 0.20 ml/ 
min kg in the HS group vs. 0.176 ± 0.096 ml/ 
min kg in the CRF group; P < 0.001), which is to 
be expected. The mean value for F ranged from 0.588 
to 0.675 in the HS group and from 0.677 to 0.764 in 
the CRF group, depending on the method of calcula- 
tion. Although no statistical differences were found in 
the biologic ti12 or CL,, in the HS and CRF groups as a 
function of the route of administration, CL,, was greater 
in seven of 10 participants after oral dosing. Therefore, 
the F value corrected for CLR (0.664 ± 0.112 for the 
HS group vs. 0.689 ± 0.149 for the CRF group) is 
probably the more accurate assessment of this pa- 
rameter. 
The Ae(0-8) and overall efficiency of bumetanide- 
induced natriuresis are listed in Tables V and VI, re- 
spectively. Bumetanide elicited an equivalent response 
in the HS and CRF groups whether taken by mouth or 
administered intravenously. Although the amount of 
sodium excreted per unit of bumetanide tended to be 
larger after oral dosing (Table VI), the difference was 
not statistically significant at the 95% confidence level, 
and may reflect the small number of participants 
studied. 
The parameters for the dose-response relationships 
of intravenous bumetanide are listed in Table VII. The 
goodness of fit was evaluated by R2 CORR and by 
visual examination of the residuals. In comparison with 
healthy subjects, patients with CRF had a significantly 
lower Emax (3.82 ± 1.13 mEq/min in the HS group vs. 
1.09 ± 0.71 mEq/min in the CRF group; P <0.005) 
and an eightfold reduction in ER50 (14.0 1.- 7.8 ig/min 
in the HS groups vs. 1.70 ± 0.87 Rg/min in the CRF 
group; P < 0.005). In the fitting of the sigmoid 
model, the first data point (i.e., the highest value for 
ER) was omitted for five participants (two in the HS 
group and three in the CRF group) because of the pres- 
ence of a counterclockwise hysteresis (Figs. 4 and 5). 
This phenomenon has been reported for bumetanide in 
dogs8'33 and humans,' and reflects the disequilibrium 
that can occur between the urine and effect compart- 
ments during the early periods after dosing. Dynamic 
parameters were not evaluated after oral dosing because 
insufficient data were available to define the full extent 
of the sigmoid-shaped curve. Nonetheless, a similar 
profile was observed for the dose-response relationship 
of bumetanide when oral and intravenous administra- 
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Table IV. Absorption and disposition characteristics of oral bumetanide in healthy subjects and patients with CRF 
NS = Not significant. 
Table V. Natriuretic effect of bumetanide in healthy 
subjects and patients with CRF after oral and 
intravenous administration 
NS = Not significant. 
tion curves were superimposed on one another in the 
HS and CRF groups (Figs. 4 and 5, respectively). 
DISCUSSION 
The pharmacokinetics and pharmacodynamics of 
bumetanide after 1 mg oral and intravenous doses have 
been studied by Marcantonio et al.' in patients with 
hepatic and renal disease. In comparison with normal 
subjects (n = 8), these investigators observed that pa- 
tients with CRF (n = 6) had higher serum concentra- 
tions of bumetanide and that the terminal t1,2 values were 
significantly prolonged. They also state that the signif- 
icant reduction in CL was attributable to the very low 
Table VI. Overall efficiency (sodium/bumetanide) in 
healthy subjects and patients with CRF after oral and 
intravenous administration 
NS = Not significant. 
CLR in these patients because the CLNR was increased. 
Despite the fact that the F values were high for both 
groups (mean of 0.89 for the HS group vs. 0.83 for the 
CRF group), subtherapeutic doses of bumetanide were 
given to the patients with CRF, resulting in a poor 
pharmacodynamic response. Subsequently, Pentikainen 
et al.' studied the pharmacokinetics of bumetanide after 
1 mg iv doses in six healthy subjects and 22 patients 
with variable degrees of CRF (creatinine clearances 
range from 0 to 54 ml/min). These investigators re- 
ported that the most important changes in bumetanide 
kinetics for patients with CRF were the low CLR and 
the high fu. As a result, significant increases were also 
Bumetanide in renal failure 641 
Oral Intravenous 
(mEq18 hr) (mEq18 hr) 
Oral Intravenous 
(mEql "kg 8 hr) (mEql g 8 hr) 
Subjects Subjects 
1 465 281 1 0.2116 0.0732 
2 266 501 2 0.0973 0.1631 
3 407 279 3 0.1297 0.0744 
4 292 365 4 0.1348 0.0864 
358 357 X 0.1434 0.0993 
-± SD 94 104 ± SD 0.0484 0.0430 
P value NS (>0.4) P value NS (>0.1) 
Patients Patients 
5 103 53.5 5 0.1520 0.0411 
6 227 203 6 0.2393 0.1703 
7 158 167 7 1.5288 0.9540 
8 180 146 8 0.6684 0.4394 
9 194 210 9 0.4832 0.2875 
10 212 225 10 0.3972 0.3775 
179 167 X 0.5782 0.3783 
± SD 44 63 ± SD 0.5000 0.3163 
P value NS (>0.2) P value NS (>0.05) 
Subjects Patients Significance (P value) 
C, (ng/ml) 179 ± 98 140 ± 64 NS 
t_ax (min) 60 0 98 ± 44 NS t (min) 23.4 ± 5.8 20.5 ± 6.4 NS 
MAT (m) 128 ± 62 113 ± 49 NS 
MAT,_ (m) 105 ± 66 92.1 ± 46.9 NS 
(mm) 85.7 ± 9.2 108 ± 32 NS 
CLR (ml/min kg) 1.71 ± 0.20 0.176 ± 0.096 <0.001 
F, 0.588 ± 0.096 
0.675 ± 0.163 
0.677 ± 0.154 
0.764 ± 0.156 
NS 
NS 
0.664 ± 0.112 0.689 ± 0.149 NS 
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Fig. 4. Mean ( ± SE) sodium excretion rate vs. urinary ex- 
cretion rate of bumetanide in healthy subjects after oral (*) 
and intravenous (*) doses. The solid line represents the com- 
puter-generated regression line based on the fitted parameters 
in Table VII. 
URINARY EXCRETION RATE (LIG/MIN) 
Fig. 5. Mean ( ± SE) sodium excretion rate vs. urinary ex- 
cretion rate of bumetanide in patients with CRF after oral (4)) 
and intravenous (*) doses. The solid line represents the com- 
puter-generated regression line based on the fitted parameters 
in Table VII. 
observed for CLR, V, and the elimination t1,2. In our 
study, changes in the patients' pharmacokinetics were 
qualitatively similar to those in the studies above,7" 
although these kinetic parameters were quantitatively 
in closer agreement to those of Marcantonio et al." for 
both healthy subjects and patients. This finding may be 
because both studies (ref. 20 and ours) involved a spe- 
cific HPLC assay in which the known metabolites of 
bumetanide were shown not to interfere with the anal- 
ysis. Likewise, the large variability in the previously 
reported clearances of bumetanide for healthy sub- 
jects6'7.19 probably reflects the use of different analytic 
methods in which drug was measured by RIA or by 
liquid scintillation counting after solvent extraction. 
Fig. 6. Relationship between bumetanide CLR and CLcR in 
healthy subjects (*) and patients with CRF (; r = 0.995; 
P < 0.001). 
CREATIN1NE CLEARANCE (mlimm) 
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Fig. 7. Relationship between corrected CI, (CLR/CL,R) and 
bumetanide fR in healthy subjects (*) and patients with CRF (; r = -0.569; P> 0.05). 
In our study, the reduction in bumetanide CL, was 
paralleled by a concomitant reduction in nephron mass, 
as demonstrated by the significant positive correlation 
between CLR and CLcR (Fig. 6; r = 0.995;P <0.001). 
However, no direct correlation could be made between 
the corrected CLR (CLR/CLcR) of bumetanide and fu (Fig. 
7; r = -0.569; P > 0.05). As a result, the corrected 
CL, of unbound bumetanide (CLR/f CLcR) was sig- 
nificantly reduced in patients with CRF (143 ± 12 for 
subjects vs. 52.0 ± 19.6 for patients; P < 0.001). Al- 
though speculative, mechanisms consistent with this 
finding include the presence of capacity-limited trans- 
port, product inhibition, and competition for active se- 
cretion between bumetanide and endogenous substances 
in the patients with azotemia. This last hypothesis is 
particularly attractive because previous investigators 
have shown that endogenous organic acids can accu- 
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Table VII. Dose-response parameters in healthy subjects and patients with CRF after intravenous bumetanide 
mulate and block the active transport pathway of fu- 
rosemide in azotemia in dogs" and humans.' 
The absorption profile of bumetanide in healthy sub- 
jects and patients with CRF was found to be quite vari- 
able, as demonstrated by the large coefficients of vari- 
ation (51% to 63%) surrounding the mean values for 
MATc0,. In addition, a time lag of approximately 20 to 
25 minutes was observed for both groups, a value in 
close agreement with those other studies in healthy sub- 
jects.'" Although the F values did not differ between 
the subjects and patients, the mean values (65% to 
70%) were smaller than those reported in previous 
studies.5'17-2° Pentikainen et al.' and Halladay et al. 17 
stated that the absorption of bumetanide was nearly 
complete (>95%) in four healthy subjects. However, 
their results are suspect because a nonspecific assay 
was used in which the drug was measured by total 
radioactivity in the various biologic fluids. Subse- 
quently, Holazo et al.19 used an RIA to determine the 
bioavailability of bumetanide tablets in 12 normal sub- 
jects. They reported that 78% and 86% of the drug 
reached the systemic circulation when calculated by the 
area and urinary excretion methods, respectively. Using 
a specific HPLC assay with fluorescence detection, 
Marcantonio et al.' also reported high F values for 
bumetanide. In eight healthy subjects the F value was 
90%'8 and in six patients with CRF the F value was 
83%.20 Unfortunately, the variability about the mean 
NS = Not significant. 
*R2 = [E(Obs)2 - /(Dev)21/(Obs)2, where 2,(Dev)2 is the residual sum of squares. 
tCORR represents the correlation between the calculated and observed sodium excretion rates. 
The sigmoid Er.x model was fit without the first data point. 
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values was not reported by these investigators. The 
discrepancy in the F value between our study and those 
of Marcantonio et al. is difficult to reconcile because 
similar HPLC assays were used. Nevertheless, this dis- 
crepancy may reflect the different doses that were used. 
It is conceivable that a dose-dependent absorption may 
be occurring at the 5 mg doses in our study, but not at 
their 1 mg doses. Other investigators51719 studied the 
bioavailability of bumetanide at doses ranging from 0.5 
to 2.0 mg. 
As observed in Tables V and VI, bumetanide elicited 
an equivalent response in the HS and CRF groups 
whether administered orally or intravenously. This 
equivalency of response occurred despite the signifi- 
cantly smaller excretion of unchanged bumetanide after 
oral dosing in healthy subjects (2166 529 lig/8 hr 
for oral vs. 3236 ± 394 p.g/8 hr for intravenous; 
P < 0.05) and patients (399 ± 266 ig/8 hr for oral vs. 
538 ± 315 jig/8 hr for intravenous; P < 0.02). Sim- 
ilar observations have been cited for bumetanidel'" 
and furosemide." However, in the case of furosemide, 
on average only 50% of the oral drug reaches the sys- 
temic circulation. This phenomenon was explained by 
Kaojarern et al., who stressed the importance of the 
slope factor of the dose-response curve on the overall 
dynamics. They observed that when the slope factor is 
<2, the maximally efficient excretion rate is less than 
the ER50. As a result, maximally efficient amounts of 
(mEqlmin) 
ER, 
(Aglmin) 
E, 
(mEqlmin) R2* CORRt 
Subjects 
1 3.30 1.74 18.5 0.120 0.978 0.980 
2 2.73 1.27 3.1 0.006 0.997 0.995 
3$ 5.35 1.64 20.7 0.060 0.998 0.999 
4$ 3.91 1.81 13.9 0.153 0.999 0.999 
3.82 1.61 14.0 0.085 0.993 0.989 
-±SD 1.13 0.24 7.8 0.065 0.010 0.008 
Patients 
5 0.30 0.62 1.81 0.007 0.998 0.992 
6t 0.70 1.86 1.66 0.122 0.980 0.934 
7 2.30 0.67 2.96 0.012 0.996 0.993 
8$ 0.72 1.02 0.59 0.031 0.988 0.965 
9$ 1.48 1.14 2.25 0.087 0.978 0.965 
10 1.08 1.32 0.92 0.110 0.994 0.990 
1.09 1.10 1.70 0.061 0.989 0.973 
±SD 0.71 0.46 0.87 0.051 0.008 0.023 
Significance (P value) P < 0.005 NS <0.005 NS 
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drug can be maintained at the active site for prolonged 
periods after oral dosing because of the absorption pro- 
file. Thus the same or perhaps a greater cumulative 
effect can be obtained with less total drug in the urine. 
This finding is consistent with our results in subjects 
and patients, and may explain the equivalency of oral 
vs. intravenous bumetanide despite an F value of 
65% to 70%. 
The lower Emax in patients with CRF (Table VII) was 
not surprising because their nephron mass is substan- 
tially reduced, as judged by the decrease in CL. How- 
ever, based on the ER50 data alone, one might be misled 
to conclude that the HS group was more resistant to 
bumetanide therapy. Instead, a tolerance effect was 
probably developed to bumetanide because of an acute 
depletion of extracellular fluid volume and electrolytes. 
Although we replaced urinary losses with isovolumetric 
amounts of fluid by mouth, the body was apparently 
not replenishing the extracellular fluid volume at an 
equal rate. Furthermore, by the time the first fluid re- 
placement was received (30 minutes after dosing), it 
may have already been too late. This hypothesis is 
supported by the occurrence of leg cramps in two of 
the healthy subjects. A similar phenomenon was also 
reported in a study by Hammarlund et al. ,3" in which 
acute tolerance developed to furosemide diuresis in rats 
and humans. In the study in the rat," the ER50 increased 
by a factor of 20 as single intravenous doses of furo- 
semide were increased from 2.5 to 100 mg/kg. In the 
study in humans,' a clockwise hysteresis was noted 
when the oral doses were taken postprandially. In ad- 
dition, the drug excretion-response curves showed par- 
allel shifts to the right, depending on the mode of ad- 
ministration of furosemide. In both of these studies, 
the renal sensitivity to furosemide was attenuated within 
a very short period of time (i.e. , minutes to hours) and 
in an unpredictable manner. An acute volume depletion 
may also explain the sharp contrast of our results in 
healthy subjects with those of Brater et al 3.8.40 Despite 
the similar values for Emax, S, and E0, the ER50 was 
approximately 10 to 14 times greater in our study. This 
discrepancy may reflect the fact that urinary losses were 
replaced intravenously in their healthy subjects and that 
lower doses were used (1 mg as compared with the 5 
mg doses in our study), thereby reducing the potential 
for volume and electrolyte depletion. 
In conclusion, the bioavailability of 5 mg doses of 
bumetanide was approximately 65% to 70% with a vari- 
ability about the mean of 15% to 20% in healthy sub- 
jects and patients with CRF. The cumulative pharma- 
codynamic effects of oral and intravenous doses were 
essentially equivalent despite the fact that a smaller 
C1AN PHARMACOL THER 
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amount of drug was delivered to the site of action after 
oral dosing. As a result, it appears that a predictable 
transition from 5 mg intravenous to oral maintenance 
regimens of bumetanide is possible in patients with 
CRF. Intravenous administration should be reserved for 
those conditions in which a more rapid onset of action 
is required. 
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